<DOC>
	<DOCNO>NCT01471015</DOCNO>
	<brief_summary>Selective head cool whole body hypothermia become standard care neonatal hypoxia-ischemia encephalopathy ( HIE ) . Despite early intervention death major neurodevelopmental disability still occur nearly 50 % infant ≥ 36 week gestational age ( GA ) treat cool . No additional therapy proven efficacious reduce brain injury impairment high risk infant . Neuroprotective strategy aim improve early childhood outcome still need . An important area study include therapy may complement neuroprotective effect hypothermia promote neuronal regeneration , recovery neurovascular remodeling . Among therapy , erythropoiesis stimulate agent ( ESA ) show provide neuroprotection , improve short long-term neurologic outcome brain injury HIE neonatal adult animal model . Parallel neuroprotective effect experimental setting , recent small clinical study suggest improve outcome ESA administration patient severe traumatic brain injury HIE . ESA may work several important mechanism include reduced inflammation , limited oxidative stress , decrease apoptosis white matter injury , well via pro-angiogenic neurogenic property . Darbepoetin alfa ( Darbe ) , recombinant human erythropoietin ( EPO ) -derived molecule , extend circulate half life comparable biological activity EPO , include activation EPO receptor . The propose study Phase I/II dose safety pharmacokinetic trial early Darbe administer concurrent hypothermia human newborn infant moderate severe birth asphyxia . The long-term objective propose research reduce mortality decrease risk long-term disability infant HIE survive beyond newborn period .</brief_summary>
	<brief_title>Darbe Administration Newborns Undergoing Cooling Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Hypoxia-Ischemia , Brain</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Infants eligible DANCE trial gestational age &gt; 36 week best obstetric estimate , &lt; 12 hour old evidence moderatesevere acute perinatal HIE . Eligibility also include criterion presently use NICU initiate hypothermia : 1 . &lt; 6 hour birth 2 . History acute perinatal event ( abruption , cord prolapse , severe fetal heart rate abnormality ) 3 . Severe fetal early ( &lt; 1 hour age ) neonatal acidosis : arterial pH ≤ 7.0 base deficit ≥ 16m mEq/ L 4 . If blood gas available blood gas &lt; 1 hour age pH 7.01 7.15 , base deficit 10 15.9 mEq/L , additional criterion require : acute perinatal event AND either 10min Apgar score ≤ 5 assist ventilation initiate birth continue least 10 minute . 1 . Major congenital and/or chromosomal abnormality 2 . Prenatal diagnosis brain abnormality hydrocephalus 3 . Severe growth restriction ( &lt; 1800g ) 4 . Central venous hematocrit &gt; 65 % , platelet count &gt; 600,000/dL , and/or neutropenia ( ANC &lt; 500 µL ) 5 . Maternal history major vascular thrombosis multiple fetal loss ( &gt; 3 spontaneous abortion ) 6 . ECMO 7 . Infant judge critically ill unlikely benefit neonatal intensive care attend neonatologist</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Hours</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hypoxic Ischemic Encephalopathy</keyword>
	<keyword>Cooling Therapy</keyword>
	<keyword>HIE</keyword>
</DOC>